<DOC>
	<DOC>NCT02057250</DOC>
	<brief_summary>Primary Objective: To collect real-use data of the sarilumab auto-injector used by rheumatoid arthritis (RA) patients. Secondary Objective: To compare the pharmacokinetic (PK) exposure of sarilumab administered by AID versus prefilled syringes (PFS).</brief_summary>
	<brief_title>To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Total study duration up to 74 weeks: screening up to 4 weeks, AID assessment phase 12 weeks, extension phase 52 weeks, post-treatment follow-up of 6 weeks. For patients not entering the extension phase, total study duration up to 22 weeks (screening, AID assessment phase and follow-up).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of rheumatoid arthritis (RA), ≥3 months disease duration Patient willing and able to selfinject Continuous treatment with 1 or a combination of nonbiologic DMARDs (except leflunomide in combination with methotrexate) Moderatetoseverely active RA Exclusion criteria: Patients&lt;18 years Prior treatment with antiinterleukin 6 (IL6) or IL6 receptor (IL6R) antagonists Treatment with tumor necrosis factor (TNF) antagonists Treatment with RAdirected biologic agents other than with a TNFα antagonist mechanism as follows: Anakinra, Abatacept, Rituximab or other celldepleting agent Prior treatment with a Janus kinase inhibitor The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>